Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TCR2 Therapeutics Inc. - Common Stock (NQ:TCRR)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TCR2 Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
Recap: TCR2 Therapeutics Q1 Earnings
Via Benzinga
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via GlobeNewswire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
What To Know About Jefferies's Downgrade of TCR2 Therapeutics
Via Benzinga
4 Analysts Have This to Say About TCR2 Therapeutics
Via Benzinga
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
Via Benzinga
Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones jumped more than 500 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
From Kahn Swick & Foti, LLC
Via Business Wire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TCR2 Therapeutics
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –
From Brodsky & Smith LLC
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
Via Benzinga
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
From TCR2 Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
Via Benzinga
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023
Via Benzinga
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
Why Is TCR2 Therapeutics Stock Trading Higher Today?
TCR² Therapeutics (NASDAQ: TCRR) shares are trading higher on Monday after the company and Adaptimmune Therapeutics (NASDAQ: ADAP) announced an agreement under which the two companies will combine to... 
Via Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of 
Via Spotlight Growth
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
A new deal offers a lifeline for TCRR stock and a compatible investment for Adaptimmune. Both companies are targeting solid cancer tumors. 
Via InvestorPlace
TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors... 
Via Newsfile
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
From TCR2 Therapeutics
Via GlobeNewswire
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
From TCR2 Therapeutics
Via GlobeNewswire
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest. 
Via InvestorPlace
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.